Clinical trial reportLancet (London, England)Published
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- Counties
- Chester County, Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Lancet (London, England)
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Crohn Disease; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method; Adult; Middle Aged; Female; Male; Young Adult; Antibodies, Monoclonal, Humanized; Maintenance Chemotherapy
- PubMed ID
- 40684778
- Added to directory
- Source checked